Blueprint Medicines Investor Relations Material
Latest events
Q1 2025
Blueprint Medicines
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Blueprint Medicines Corp
Access all reports
Blueprint Medicines Corp. is a biopharmaceutical company focused on developing targeted therapies for genomically defined cancers and rare diseases. The company utilizes precision medicine approaches to design small-molecule drugs that inhibit specific genetic drivers of disease. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Blueprint Medicines Corp
Q4 2024
Blueprint Medicines Corp
Q4 2024
Blueprint Medicines Corp
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
BPMC
Country
🇺🇸 United States